Compare MSGM & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSGM | CLRB |
|---|---|---|
| Founded | 2018 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 12.0M |
| IPO Year | 2020 | 2008 |
| Metric | MSGM | CLRB |
|---|---|---|
| Price | $4.30 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 47.2K | ★ 175.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 252.13 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $741,000.00 | N/A |
| Revenue This Year | $69.73 | N/A |
| Revenue Next Year | $146.81 | N/A |
| P/E Ratio | $72.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.11 | $0.29 |
| 52 Week High | $5.78 | $10.19 |
| Indicator | MSGM | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 47.36 | 36.29 |
| Support Level | $3.95 | N/A |
| Resistance Level | $4.57 | $3.40 |
| Average True Range (ATR) | 0.22 | 0.19 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 63.64 | 14.95 |
Motorsport Games Inc is a motorsport network company that combines engaging video games with esports competitions and content for racing fans and gamers around the globe. The company has its reportable segments into the development and publishing of interactive racing video games, entertainment content and services, and the organization and facilitation of esports tournaments, competitions, and events for licensed racing games as well as on behalf of third-party video game racing series and other video game publishers. The majority of the revenue is earned from Gaming.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.